These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 28262275)

  • 1. In reply to: Anti-HER2 neoadjuvant treatment may have an impact on discordance between preoperative core needle biopsy and surgical specimen in early breast cancer.
    Meattini I; Francolini G; Livi L; Nori J
    Eur J Surg Oncol; 2017 Jun; 43(6):1143-1144. PubMed ID: 28262275
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-HER2 neoadjuvant treatment may have an impact on discordance between preoperative core needle biopsy and surgical specimen in early breast cancer.
    Altundag K
    Eur J Surg Oncol; 2017 Jun; 43(6):1142. PubMed ID: 28279527
    [No Abstract]   [Full Text] [Related]  

  • 3. Reliability of histological malignancy grade, ER and HER2 status on core needle biopsy vs surgical specimen in breast cancer.
    Munch-Petersen HD; Rasmussen BB; Balslev E
    APMIS; 2014 Sep; 122(9):750-4. PubMed ID: 24372587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer.
    Chen HR; Wu YT; Yu QB; Yang YY; Wei YX; Li HY; Wu KN; Kong LQ
    World J Surg Oncol; 2017 Oct; 15(1):189. PubMed ID: 29052527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of molecular subtypes classification concordance between preoperative core needle biopsy and surgical specimen on early breast cancer management: Single-institution experience and review of published literature.
    Meattini I; Bicchierai G; Saieva C; De Benedetto D; Desideri I; Becherini C; Abdulcadir D; Vanzi E; Boeri C; Gabbrielli S; Lucci F; Sanchez L; Casella D; Bernini M; Orzalesi L; Vezzosi V; Greto D; Mangoni M; Bianchi S; Livi L; Nori J
    Eur J Surg Oncol; 2017 Apr; 43(4):642-648. PubMed ID: 27889196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States $35 Million/y.
    VandenBussche CJ; Cimino-Mathews A; Park BH; Emens LA; Tsangaris TN; Argani P
    Am J Surg Pathol; 2016 Aug; 40(8):1090-9. PubMed ID: 27299796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors.
    Nakamura R; Yamamoto N; Shiina N; Miyaki T; Ikebe D; Itami M; Shida T; Miyazaki M
    Breast; 2016 Apr; 26():141-7. PubMed ID: 26732051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing?
    Rakha EA; Pigera M; Shin SJ; D'Alfonso T; Ellis IO; Lee AH
    Histopathology; 2016 Jul; 69(1):20-4. PubMed ID: 26542743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
    D'Alfonso T; Liu YF; Monni S; Rosen PP; Shin SJ
    Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of preoperative evaluation of tumour grade by core needle biopsy on clinical risk assessment and patient selection for adjuvant systemic treatment in breast cancer.
    Waaijer L; Willems SM; Verkooijen HM; Buck DB; van der Pol CC; van Diest PJ; Witkamp AJ
    Br J Surg; 2015 Aug; 102(9):1048-55. PubMed ID: 26176340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnostic value of core needle biopsy before neoadjuvant chemotherapy for breast cancer].
    Zheng S; Zhang BL; Zou SM; Lin DM; Xue LY; Luo W; Lu N
    Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):99-102. PubMed ID: 18681320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer.
    Asogan AB; Hong GS; Arni Prabhakaran SK
    Singapore Med J; 2017 Mar; 58(3):145-149. PubMed ID: 27029805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discrepancies between HER2 assessment from core needle biopsies and surgical specimens of invasive ductal breast carcinoma.
    Wojnar A; Bartosz Puła B; Podhorska-Okołów M; Dzięgiel P
    Adv Clin Exp Med; 2013; 22(1):27-31. PubMed ID: 23468259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?
    Xian Z; Quinones AK; Tozbikian G; Zynger DL
    Hum Pathol; 2017 Apr; 62():215-221. PubMed ID: 28041972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reflex estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/Her2) analysis of breast cancers in needle core biopsy specimens dramatically increases health care costs.
    VandenBussche CJ; Cimino-Mathews A; Park BH; Emens LA; Tsangaris TN; Argani P
    Am J Surg Pathol; 2015 Jul; 39(7):939-47. PubMed ID: 25871620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical importance of discordance of hormone receptors and Her2/neu status after neoadjuvant chemotherapy in breast cancer.
    Basak Oven Ustaalioglu B; Aker Vardar F; Bilici A; Gurleyik G; Erkol B; Kefeli U; Aliustaoglu M
    J BUON; 2014; 19(4):879-86. PubMed ID: 25536590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast.
    Lee AH; Key HP; Bell JA; Hodi Z; Ellis IO
    Histopathology; 2012 May; 60(6):880-4. PubMed ID: 22320892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer.
    Yang YF; Liao YY; Li LQ; Xie SR; Xie YF; Peng NF
    Pathol Res Pract; 2013 Dec; 209(12):797-802. PubMed ID: 24183366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.